| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Advances in Brief |
Departments of Surgery [P. P. L., J. H. H.], Pathology [R. I. B., A. C. H., J. E. B., M. L.], and Human Genetics [M. L.], Memorial Sloan-Kettering Cancer Center, New York, New York 10021
The t(11;22)(q24;q12) translocation is present in up to 95% of cases of Ewing’s sarcoma and results in the formation of an EWS-FLI1 fusion gene which encodes a chimeric transcription factor. The proximate role of EWS-FLI1 in the pathogenesis of Ewing’s sarcoma is thought to involve the activation of as yet largely unknown target genes. Many alternative forms of EWS-FLI1 exist because of variations in the locations of the EWS and FLI1 genomic breakpoints. The most common form, designated "type 1," consists of the first seven exons of EWS joined to exons 6–9 of FLI1 and accounts for approximately 60% of cases. The "type 2" EWS-FLI1 fusion also includes FLI1 exon 5 and is present in another 25%. We and others have observed previously that the type 1 fusion is associated with a significantly better prognosis than the other fusion types. Because EWS-FLI1 is an aberrant transcription factor, we investigated whether these differences in clinical behavior may be correlated to functional differences by comparing transactivation by the type 1 EWS-FLI1 with other types in both heterologous cells (HeLa, NIH3T3) and homologous cells (Ewing’s sarcoma cell lines). In a panel of seven Ewing’s sarcoma cell lines, we found transactivation of a transiently transfected FLI1-responsive reporter construct to be significantly lower in cell lines with the type 1 fusion than in cell lines with the type 2 fusion (P = 0.003). Cotransfection of the same reporter construct with each of a series of seven EWS-FLI1 expression constructs (corresponding to the two major fusion types and five less common types) also showed that type 1 EWS-FLI1 was a significantly weaker transactivator than the type 2 product in both HeLa and NIH3T3 cells (P = 0.003, and P = 0.033, respectively). Electromobility shift assays showed equivalent binding of the type 1 and type 2 EWS-FLI1 to the consensus FLI1-responsive binding site, indicating that differences in transactivation were not due simply to differences in DNA binding affinity. The finding that the type 1 EWS-FLI1 fusion, associated with less aggressive clinical behavior, encodes a less active chimeric transcription factor may provide the basis for a molecular explanation of clinical heterogeneity in Ewing’s sarcoma.
This article has been cited by other articles:
|
|
 |
|
  Y. Miyagawa, H. Okita, H. Nakaijima, Y. Horiuchi, B. Sato, T. Taguchi, M. Toyoda, Y. U. Katagiri, J. Fujimoto, J.-i. Hata, et al. Inducible Expression of Chimeric EWS/ETS Proteins Confers Ewing's Family Tumor-Like Phenotypes to Human Mesenchymal Progenitor Cells Mol. Cell. Biol., April 1, 2008; 28(7): 2125 - 2137. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. Slater and J. Shipley Clinical relevance of molecular genetics to paediatric sarcomas J. Clin. Pathol., November 1, 2007; 60(11): 1187 - 1194. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Iwamoto Diagnosis and Treatment of Ewing's Sarcoma Jpn. J. Clin. Oncol., February 1, 2007; 37(2): 79 - 89. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Riggi, L. Cironi, P. Provero, M.-L. Suva, K. Kaloulis, C. Garcia-Echeverria, F. Hoffmann, A. Trumpp, and I. Stamenkovic Development of Ewing's Sarcoma from Primary Bone Marrow-Derived Mesenchymal Progenitor Cells Cancer Res., December 15, 2005; 65(24): 11459 - 11468. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H.-Y. Huang, P. B. Illei, Z. Zhao, M. Mazumdar, A. G. Huvos, J. H. Healey, L. H. Wexler, R. Gorlick, P. Meyers, and M. Ladanyi Ewing Sarcomas With p53 Mutation or p16/p14ARF Homozygous Deletion: A Highly Lethal Subset Associated With Poor Chemoresponse J. Clin. Oncol., January 20, 2005; 23(3): 548 - 558. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C.-C. Chang and V. B. Shidham Molecular Genetics of Pediatric Soft Tissue Tumors: Clinical Application J. Mol. Diagn., August 1, 2003; 5(3): 143 - 154. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S A Burchill Ewing's sarcoma: diagnostic, prognostic, and therapeutic implications of molecular abnormalities J. Clin. Pathol., February 1, 2003; 56(2): 96 - 102. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Ozaki, K.-L. Schaefer, D. Wai, R. Yokoyama, S. Ahrens, R. Diallo, T. Hasegawa, T. Shimoda, S. Hirohashi, A. Kawai, et al. Population-based genetic alterations in Ewing's tumors from Japanese and European Caucasian patients Ann. Onc., October 1, 2002; 13(10): 1656 - 1664. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Hosaka, Y. Nakashima, K. Kusuzaki, H. Murata, T. Nakayama, T. Nakamata, T. Aoyama, T. Okamoto, K. Nishijo, N. Araki, et al. A Novel Type of EWS-CHOP Fusion Gene in Two Cases of Myxoid Liposarcoma J. Mol. Diagn., August 1, 2002; 4(3): 164 - 171. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. J. Cummings, N. M. Brown, and T. T. Stenzel TaqMan Junction Probes and the Reverse Transcriptase Polymerase Chain Reaction: Detection of Alveolar Rhabdomyosarcoma, Synovial Sarcoma, and Desmoplastic Small Round Cell Tumor Ann. Clin. Lab. Sci., July 1, 2002; 32(3): 219 - 224. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Ladanyi, C. R. Antonescu, D. H. Leung, J. M. Woodruff, A. Kawai, J. H. Healey, M. F. Brennan, J. A. Bridge, J. R. Neff, F. G. Barr, et al. Impact of SYT-SSX Fusion Type on the Clinical Behavior of Synovial Sarcoma: A Multi-Institutional Retrospective Study of 243 Patients Cancer Res., January 1, 2002; 62(1): 135 - 140. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. R. Antonescu, S. J. Tschernyavsky, R. Decuseara, D. H. Leung, J. M. Woodruff, M. F. Brennan, J. A. Bridge, J. R. Neff, J. R. Goldblum, and M. Ladanyi Prognostic Impact of P53 Status, TLS-CHOP Fusion Transcript Structure, and Histological Grade in Myxoid Liposarcoma: A Molecular and Clinicopathologic Study of 82 Cases Clin. Cancer Res., December 1, 2001; 7(12): 3977 - 3987. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Heimann, H. El Housni, G. Ogur, M. A. J. Weterman, E. M. Petty, and G. Vassart Fusion of a Novel Gene, RCC17, to the TFE3 gene in t(X;17)(p11.2;q25.3)-bearing Papillary Renal Cell Carcinomas Cancer Res., May 1, 2001; 61(10): 4130 - 4135. [Abstract] [Full Text]
|
|
|
|
 |
|
 E. de Alava and J. Pardo Ewing Tumor: Tumor Biology and Clinical Applications International Journal of Surgical Pathology, January 1, 2001; 9(1): 7 - 17. [Abstract] [PDF]
|
|
|
|
|
|
H. Kovar, F. J. Fallaux, I. Pribill, D. Jugovic, S. Bartl, P. F. Ambros, D. N. T. Aryee, J. C. A. G. Wiegant, and R. C. Hoeben Adenovirus E1A Does Not Induce the Ewing Tumor-associated Gene Fusion EWS-FLI1 Cancer Res., March 1, 2000; 60(6): 1557 - 1560. [Abstract] [Full Text]
|
|
|
|
 |
|
 E. de Alava, A. Panizo, C. R. Antonescu, A. G. Huvos, F. J. Pardo-Mindan, F. G. Barr, and M. Ladanyi Association of EWS-FLI1 Type 1 Fusion with Lower Proliferative Rate in Ewing’s Sarcoma Am. J. Pathol., March 1, 2000; 156(3): 849 - 855. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. de Alava and W. L. Gerald Molecular Biology of the Ewing’s Sarcoma/Primitive Neuroectodermal Tumor Family J. Clin. Oncol., January 5, 2000; 18(1): 204 - 204. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
